Castagna Michael

Avg. Two Year Performance

(43%) Avg. Purchase Return
(20%) Compound
No sale track record
1 Mo3 Mo6 Mo1 Yr2 Yr
Average Purchase Return(3%)(7%)6%(46%)(43%)
Purchase Success Rate3 of 53 of 51 of 50 of 50 of 5
Average Sale Return0%0%0%0%0%
Sale Success Rate0 of 50 of 50 of 50 of 50 of 5

MannKind Corp.

Drugs » Biotechnology

Chief Executive Officer, Director:

Holdings: 2.18M shares

Sentiment

Insider Trading Sentiment: Hold

Avg. Two Year Performance

No purchase track record
No sale track record

Last Three Months:

0 Net Amount
Buy:0--
Sell:0--